{"hq_id":"hq-p-spe-000210","name":"Silicone Breast Implant (BIA-ALCL Risk, Textured Surface, Gel Migration, Capsular Contracture, FDA Black Box Warning)","category":{"primary":"specialty_hazard","secondary":"breast_implant","tags":["silicone","breast implant","BIA-ALCL","anaplastic large cell lymphoma","textured","capsular contracture","gel bleed","rupture","FDA black box","breast implant illness"]},"product_tier":"SPE","overall_risk_level":"moderate","description":"Silicone gel-filled breast implants are among the most studied medical devices in history, with over 400,000 implanted annually in the United States for augmentation and reconstruction. In 2011, the FDA identified a rare but serious association between textured-surface breast implants and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a T-cell lymphoma of the peri-implant capsule with an estimated incidence of 1 in 2,207 to 1 in 86,029 depending on surface texturing type. Allergan Biocell textured implants were recalled worldwide in 2019 after accounting for approximately 80% of all BIA-ALCL cases. Beyond BIA-ALCL, silicone breast implants are associated with capsular contracture (10-20% incidence at 10 years), gel bleed (microscopic silicone migration through intact shells), implant rupture (10-15% at 10 years requiring MRI screening), and a constellation of systemic symptoms termed 'breast implant illness' (BII) — fatigue, cognitive dysfunction, joint pain, and autoimmune-like symptoms — that remains scientifically controversial but is reported by thousands of patients. The FDA issued a black box warning for breast implants in 2020 and mandated a patient decision checklist for informed consent.","synthesis":{"derived_risk_level":"insufficient_data","synthesis_confidence":0,"synthesis_method":"none","context_source":null,"compounds_resolved":0,"compounds_total":0,"synthesis_date":"2026-05-09","synthesis_version":"1.2.0","methodology_note":"exposure_modifier and adjusted_magnitude are computed from ALETHEIA-calibrated heuristics (route × duration × frequency multipliers, clamped to [0.5, 1.4]). Multipliers are directionally informed by EPA Exposure Factors Handbook (2011) and CalEPA OEHHA but are not regulatory consensus. See /api/methodology for full disclosure."},"hazard_summary":{"sensitive_populations":"patients with textured-surface implants (especially Allergan Biocell), patients with family history of lymphoma or autoimmune disease, patients unable to comply with MRI screening schedule","overall_risk":"moderate","primary_concerns":["BIA-ALCL: rare but potentially fatal T-cell lymphoma linked to textured implants — 1:2,207 incidence for highest-risk surface types","Capsular contracture affects 10-20% of patients at 10 years, often requiring revision surgery","Gel bleed and rupture: silicone migration beyond capsule detected in lymph nodes and distant tissues","FDA black box warning (2020) — unprecedented for a cosmetic/reconstructive device"],"exposure_routes":"Local (implant-tissue interface — chronic inflammatory response to silicone shell and gel). Systemic (silicone gel migration through lymphatic and hematogenous routes after rupture or gel bleed)."},"exposure":{"routes":["systemic","local"],"contact_types":["implant_chronic","systemic_migration"],"users":["patient_surgical","adult_female"],"duration":"chronic","frequency":"continuous_lifetime","scenarios":["Textured implant recipient: chronic BIA-ALCL risk — T-cell lymphoma developing in peri-implant capsule 7-10 years post-implantation","Silicone gel rupture: gel migration beyond capsule into axillary lymph nodes, chest wall, and distant tissues","Capsular contracture: progressive fibrous capsule formation causing implant distortion, pain, and hardening","Systemic symptoms: fatigue, cognitive dysfunction, and autoimmune-like manifestations reported as 'breast implant illness'"],"notes":"BIA-ALCL: first FDA communication 2011; Allergan Biocell recall July 2019 (worldwide). WHO classified BIA-ALCL as a distinct lymphoma entity in 2016 revision of lymphoid neoplasms. Incidence: 1:2,207 (Allergan Biocell macro-textured) to 1:86,029 (micro-textured). Treatment: total capsulectomy with implant removal — 93% complete remission when confined to capsule. Capsular contracture: Baker Grade III-IV in 10-20% at 10 years. Gel bleed: microscopic silicone migration through intact shell — detectable in periprosthetic tissue in virtually all silicone implants. Rupture: 10-15% at 10 years; FDA recommends MRI screening at 5-6 years post-implantation and every 2-3 years thereafter. BII: no diagnostic criteria; FDA acknowledges patient-reported symptoms without confirming causation. FDA black box warning (October 2020): mandates patient decision checklist, BIA-ALCL risk disclosure, rupture screening recommendations."},"consumer_guidance":{"usage_warning":"Patients considering breast implants must review the FDA-mandated patient decision checklist and discuss BIA-ALCL risk, capsular contracture rates, rupture screening requirements (MRI at 5-6 years then every 2-3 years), and the uncertain etiology of breast implant illness with their surgeon. Patients with existing textured implants should not panic but should report any new peri-implant swelling, pain, or lump to their surgeon immediately for ultrasound and possible capsule fluid analysis. Smooth-surface implants carry lower BIA-ALCL risk based on current evidence.","safer_alternatives":["Smooth-surface silicone implants (lower BIA-ALCL risk than textured)","Saline-filled implants (deflation is immediately apparent; no gel migration risk)","Autologous tissue reconstruction (DIEP flap, TRAM flap) for post-mastectomy patients","Fat grafting for modest augmentation without implant-related risks"]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA Black Box Warning for Breast Implants and Allergan Biocell Recall","citation":"FDA Safety Communication October 27, 2020; 21 CFR 878.3530; Allergan Worldwide Recall July 24, 2019","requirements":"FDA mandated black box warning (strongest FDA warning) for all breast implants in 2020. Patient decision checklist required at consultation (informed consent documentation). Allergan Biocell textured implants voluntarily recalled worldwide in 2019. FDA recommends MRI screening for silicone implant rupture at 5-6 years post-surgery and every 2-3 years thereafter. Manufacturers must submit post-approval studies with long-term follow-up.","compliance_status":null,"effective_date":"2020-10-27","enforcing_agency":"FDA Center for Devices and Radiological Health","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":false,"disposal_guidance":"Explanted breast implants are medical waste — dispose per facility protocol. Intact implants should be returned to manufacturer for failure analysis if removed for suspected rupture or BIA-ALCL.","hazardous_waste":false,"expected_lifespan":"No lifetime device — FDA states implants are not expected to last a lifetime; average replacement at 10-15 years"},"formulation":{"form":"varies","key_ingredients":[],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[],"identifiers":{"common_names":["silicone breast implant (bia-alcl risk, textured surface, gel migration, capsular contracture, fda black box warning)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[],"brand_examples_disclaimer":null,"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-26"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-26","timestamp":"2026-05-14T01:22:38.167Z"}}